...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: RVXOT

Carry forward from RVX HUB

"We must be careful as this is starting to slip into Zenith discussion of which we are on the wrong Board. Quickly though without taking the time to look back, I believe the answer to your second part is any new shareholder benefits from the Royalty Preferred Shares as we don't own them personally. They are an asset of ZCC so any new shareholder would benefit from that asset. Royalties would be paid to ZCC and become assets of all ZCC shareholders. In theory though, any share offering price is supposed to have a value included in it for that ZCC asset and that is where the new shareholders buy into that asset."

I don't think it would be fair for new prospective  (IPO)Zenith Shareholders to capitalize on the RVX/ RPS. 

IMO....Koo

 

 

 

 

 

Share
New Message
Please login to post a reply